On September 12, 2026, 60 Degrees Pharmaceuticals submitted a Statement of Interest to the FDA requesting a Commissioner’s National Priority Voucher for tafenoquine (ARAKODA) as a treatment for babesiosis. The company cites compelling efficacy signals from published case reports and an expanded access study where all three evaluable patients were cured. A randomized controlled trial is complete, with Data Safety Monitoring Board analysis scheduled for October 1, 2026. If successful, the company targets supplemental New Drug Application submission in March–April 2027, aiming for approval before the 2027 tick season. This biopharmaceutical company develops and commercializes pharmaceutical products.

60 Degrees Pharmaceuticals, Inc. filed a Form 8-K on September 8, 2026, to furnish an updated investor presentation dated for the same day under Item 7.01 of Regulation FD. The presentation outlines the company's strategy to expand its marketed antimalarial product ARAKODA (tafenoquine) into treatments for tick-borne diseases, specifically babesiosis. It details a commercial base generating $208k in Q2 2026 net product revenue and highlights a July 31, 2026 private placement that raised approximately $1.0M at $1.74 per share. The company reports pro forma cash and equivalents of roughly $1.0M as of late July, providing an operating runway into early October 2026. The filing also notes a Series A non-voting convertible preferred stock balance with a 6% cumulative dividend following a Knight conversion. This biopharmaceutical company focuses on targeted therapies for vector-borne diseases.

On July 30, 2026, 60 Degrees Pharmaceuticals entered into a Securities Purchase Agreement for a private placement closing on July 31, 2026. The company issued approximately $1.0 million in gross proceeds by selling 191,571 shares of common stock and pre-funded warrants to purchase 383,142 shares at $1.74 per share. The offering included Series A and B warrants to purchase up to 574,413 shares each, exercisable at $1.49 per share with expiration periods of five years and twenty-four months respectively. Proceeds will fund working capital, general operations, and research and development. H.C. Wainwright & Co. served as the exclusive placement agent. The company operates in the pharmaceutical industry, developing and commercializing medicines for vector-borne diseases.